Novel therapeutic combinations comprising derivatives of oxazaphosphorines for the treatment of cancer
WO2021063948A1
Microbial compositions for improving the efficacy of anticancer treatments based on immune checkpoint inhibitors and/or tyrosine kinase inhibitors and markers of responsiveness to such treatments
WO2021048315A1
Use of duox1 inhibitors for treating cancer
WO2021013764A1
P21 expressing monocytes for cancer cell therapy
WO2020109627A1
Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
WO2020099650A1
Madrasin-derivative compounds, composition and uses thereof for treating cancer
KR20200124661A
Use of minaphrine to reduce tumor growth
EP3659672A1
Combined use of selective serotonin reuptake inhibitors and hematopoietic growth factors for treating hematopoietic diseases
EP3629023A1
Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
EP3655542A1
Method for assessing the response to pd-1/pdl-1 targeting drugs
CA3068905A1
Injectable water-in-oil emulsions and uses thereof
WO2019012147A1
A radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-pd-1/pd-l1
CN111094977A
Imaging tools based on imaging omics to monitor tumor lymphocyte infiltration and prognosis in anti-PD-1/PD-L1 treated tumor patients
CN110913897A
Human endogenous retroviral proteins
FR3082418A1
DEVICE FOR CONNECTING A SERUM BASE TO A WHEELCHAIR, ASSOCIATED CONNECTION ASSEMBLY
AU2018251949A1
Compounds, composition and uses thereof for treating cancer
CN110462401A
The purposes that the reversal reinforcing agent of cell is used to keep tumour sensitive to radiotherapy
EP3505177A1
Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancer
KR20190118151A
Microorganism composition as a marker of responsiveness to anti-PD1 / PD-L1 / PD-L2 antibodies, and the use of microbial modulators to improve the efficacy of anti-PD1 / PD-L1 / PD-L2 Ab-based therapy
EP3476396A1
Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
